Related Experiment Videos
[Chronic kidney disease and statins]
1Klinika za unutarnje bolesti, Klinicka bolnica "Merkur", Zagreb. mirjana.sabljar-matovinovic@zg.htnet.hr
Insights
Dyslipidemia increases the risk of developing kidney disease and worsens its progression. Statin therapy shows promise in reducing cardiovascular risk and slowing chronic kidney disease (CKD) progression, particularly in moderate stages.
Area of Science:
- Nephrology
- Cardiology
- Endocrinology
Context:
- Dyslipidemia is a significant risk factor for the initial development and progression of kidney disease.
- Chronic kidney disease (CKD) and dyslipidemia frequently coexist, both independently increasing cardiovascular disease (CVD) risk.
- A strong correlation exists between the severity of renal insufficiency and cardiovascular disease incidence.
Purpose:
- To evaluate the role of statin therapy in managing cardiovascular risk and disease progression in patients with CKD.
- To investigate the efficacy of statins in modifying the course of kidney disease, especially in those with moderate renal impairment.
Summary:
- Dyslipidemia contributes to new-onset renal disease and accelerates functional decline in diabetic and non-diabetic kidney disease.
- Statin therapy is suggested to reduce cardiovascular risk and potentially alter CKD progression, particularly in moderate renal impairment.
- Further large-scale trials are required to confirm the benefits of statins across various stages of renal insufficiency.
Impact:
- Statin therapy may offer a therapeutic strategy to mitigate cardiovascular complications in CKD patients.
- Understanding the impact of statins on CKD progression could lead to improved patient outcomes and reduced healthcare burden.
- Ongoing trials are crucial for establishing definitive guidelines on statin use in managing CKD and its associated cardiovascular risks.
Abstract:
Dyslipidemia is a risk factor for de novo occurrence of renal disease in apparently healthy population, and diabetes, and contributes to progressive decline of renal function in diabetic and nondiabetic kidney disease. Chronic kidney disease and dyslipidemia, frequently occurring together, are independent cardiovascular risk factors. There is a strong association between the level of renal insufficiency and cardiovascular disease. According to available evidence, statin therapy may reduce cardiovascular risk in chronic kidney disease as well as modify its course, especially in patients with moderate impairment of renal function. However, all these findings must be examined in large-scale trials in patients with chronic renal disease and different stages of renal insufficiency. There are several on-going trials aimed at determing the role of statin therapy in this specific population, and confirming its efficacy in reducing cardiovascular risk and halting the progression of chronic kidney disease.
Related Concept Videos
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease II: Clinical Manifestations
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Chronic Kidney Disease IV: Nursing Management